Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a poxvectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria

Journal of Infectious Diseases

Volumn 177, Issue 6, 1998, Pages 1664-1673

  Ockenhouse, Christian F ^a   Sun, Pei Fang ^f   Lanar, David E ^f   Wellde, Bruce T ^f   Ted Hall, B ^f   Kester, Kent ^f   Stoute, Jose A ^f   Magill, Alan ^f   Krzych, Urszula ^f   Farley, Linda ^f   Wirtz, Robert A ^b   Sadoff, Jerald C ^f   Kaslow, David C ^f   Kumar, Sanjai ^f   Preston Church, L W ^c   Crutcher, James M ^d   Wizel, Benjamin ^e   Hoffman, Stephen ^f   Lalvani, Ajit ^f   Hill, Adrian V S ^f   Tine, John A ^f   Guito, Kenneth P ^f   De Taisne, Charles ^f   Anders, Robin ^f   Horii, Toshihiro ^f   Paoletti, Enzo ^f   Ballou, W Ripley ^f   more..

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c MICHIGAN STATE UNIVERSITY   (United States)

^d OKLAHOMA STATE DEPARTMENT OF HEALTH   (United States)

^e UNIVERSITY OF GEORGIA   (United States)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

MALARIA VACCINE; NEUTRALIZING ANTIBODY; PARASITE ANTIGEN; SODIUM CHLORIDE; VIRUS VECTOR;

ADULT; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; FEMALE; FEVER; GOOD MANUFACTURING PRACTICE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNOGENICITY; INJECTION PAIN; INTRAMUSCULAR DRUG ADMINISTRATION; MALAISE; MALARIA FALCIPARUM; MALE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; VACCINATION; VACCINIA VIRUS; VIRUS ATTENUATION; VIRUS GENOME;

EID: 17344363385     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/515331     Document Type: Article

References (16)

1. Sturchler D. How much malaria is there worldwide? Parasitol Today 1989;5:39-40.
2. Ballou WR, Hoffman SL, Sherwood JA, et al. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet 1987;1:1277-81.
3. Herrington DA, Clyde DF, Losonsky G, et al. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature 1987;328:257-9.
4. Stoute JA, Slaqui M, Heppner DG, et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N Engl J Med 1997;336:86-91.
5. Perkus ME, Piccin A, Lipinskas BR, Paoletti E. Recombinant vaccinia virus: immunization against multiple pathogens. Science 1985;229:981-4.
6. Tartaglia J, Perkus ME, Taylor J, et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology 1992;188:217-32.
7. Tine JA, Lanar DE, Smith DM, et al. NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. Infect Immun 1996;64:3833-44.
8. Barr PJ, Green KM, Gibson HL, Bathurst IC, Quakyi IA, Kasloiv DC. Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals. J Exp Med 1991;174:1203-8.
9. Sugiyama T, Suzue K, Okamoto M, Inselburg J, Tai K, Horii T. Production of recombinant SERA proteins of Plasmodium falciparum in Escherichia coli by using synthetic genes. Vaccine 1996;14:1069-76.
10. Kumar S, Yadava A, Keister DB, et al. Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys. Mol Med 1995;3:325-32.
11. Wirtz RA, Ballou WR, Schneider I, et al. Plasmodium falciparum: immunogenicity of circumsporozoite protein constructs produced in Escherichia coli. Exp Parasitol 1987;63:166-72.
12. Krzych U, Lyon JA, Jareed T, et al. T lymphocytes from volunteers immunized with irradiated Plasmodium falciparum sporozoites recognize liver and blood stage malaria antigens. J Immunol 1995;155:4072-7.
13. Cox WI, Tartaglia J, Paoletti E. Poxvirus recombinants as live vaccines. In: Binns MM, Smith GL, eds. Recombinant poxviruses. Boca Raton, FL: CRC Press, 1992:123-62.
14. Tartaglia J, Pincus S, Paoletti E. Poxvirus-based vectors as vaccine candidates. Crit Rev Immunol 1990;10:13-30.
15. Yewdell JW, Rennick JR, Smith GL, Moss B. Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci USA 1985;82:1785-9.
16. Zarling JM, Morton W, Moran PA, McCLure J, Kosowski SG, Hu SL. T-cell responses to human AIDS virus in macaques immunized with recombinant vaccinia viruses. Nature 1987;323:344-6.